Lloyd A. Rowland

This profile gathers the share dealings of Lloyd A. Rowland across 3 companies, led by Amylin Pharmaceuticals Inc, CytomX Therapeutics, Inc. and Xencor Inc. The record holds 113 filings, for trades running from 30 December 2005 to 18 March 2025.

Both buying and selling appear: 1 purchase worth €82k, against 41 sales worth €2.1M. Netting one side against the other leaves €2.0M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 22 share grants and 39 option exercises. So far in 2025, the count stands at no purchases and 1 sale.

The record was last updated on 20 March 2025 with an open-market sale (€5,597) in CytomX Therapeutics, Inc. The most recent open-market purchase was published on 5 March 2019, 2,790 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.